Physiologically based modelling and prediction of drug interactions.

A major challenge for drug development and environmental or occupational health is the prediction of pharmacokinetic and pharmacodynamic interactions between drugs, natural chemicals or environmental contaminants. This article reviews briefly past developments in the area of physiologically based pharmacokinetic (PBPK) modelling of interactions. It also demonstrates a systems biology approach to the question, and the capabilities of new software tools to facilitate that development. Individual Systems Biology Markup Language models of metabolic pathways can now be automatically merged and coupled to a template PBPK pharmacokinetic model, using for example the GNU MCSim software. The global model generated is very efficient and able to simulate the interactions between a theoretically unlimited number of substances. Development time and the number of model parameter increase only linearly with the number of substances considered, even though the number of possible interactions increases exponentially.

[1]  Raymond S. H. Yang,et al.  Exploration of an interaction threshold for the joint toxicity of trichloroethylene and 1,1-dichloroethylene: utilization of a PBPK model , 2009, Archives of Toxicology.

[2]  Leon Aarons,et al.  Drug–drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[3]  George Loizou,et al.  Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  Jeffrey W Fisher,et al.  A PBPK Modeling Assessment of the Competitive Metabolic Interactions of JP-8 Vapor with Two Constituents, m-Xylene and Ethylbenzene , 2007, Inhalation toxicology.

[5]  M. Kamijima,et al.  Physiologically Based Pharmacokinetic Modeling of Metabolic Interactions between n‐Hexane and Toluene in Humans , 1998 .

[6]  S. Wrighton,et al.  Physiological approaches to the prediction of drug-drug interactions in study populations. , 2003, Current drug metabolism.

[7]  P. Bonnabry,et al.  Quantitative Drug Interactions Prediction System (Q-DIPS) , 2001, Clinical pharmacokinetics.

[8]  F Y Bois,et al.  Precision and sensitivity of pharmacokinetic models for cancer risk assessment: tetrachloroethylene in mice, rats, and humans. , 1990, Toxicology and applied pharmacology.

[9]  P. Vasseur,et al.  Optimal pollution control strategies in the presence of interacting toxicants , 1988 .

[10]  A. Rostami-Hodjegan,et al.  'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. , 2004, Drug discovery today. Technologies.

[11]  George Loizou,et al.  Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. , 2008, Regulatory toxicology and pharmacology : RTP.

[12]  R Tardif,et al.  Physiologically-based pharmacokinetic modeling of a mixture of toluene and xylene in humans. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.

[13]  W Slob,et al.  A generic toxicokinetic model for persistent lipophilic compounds in humans: an application to TCDD. , 1996, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[14]  J. Gallo,et al.  Physiological pharmacokinetic modeling of inhaled trichloroethylene in rats. , 1991, Toxicology and applied pharmacology.

[15]  Frédéric Y. Bois,et al.  GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models , 2009, Bioinform..

[16]  Thierry Lavé,et al.  Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. , 2005, Basic & clinical pharmacology & toxicology.

[17]  Per B. Brockhoff,et al.  In silico prediction of cytochrome P450 inhibitors , 2006 .

[18]  Kairui Feng,et al.  The Simcyp® Population-based ADME Simulator , 2009 .

[19]  Paavo Honkakoski,et al.  Inhibition and induction of human cytochrome P450 enzymes: current status , 2008, Archives of Toxicology.

[20]  C. Yeung,et al.  Qualitative Analysis of the Role of Metabolites in Inhibitory Drug‐Drug Interactions: literature evaluation based on the Metabolism and Transport Drug Interaction Database , 2009, Chemical research in toxicology.

[21]  Don R. Maszle,et al.  MCSim: A Monte Carlo Simulation Program , 1997 .

[22]  S. Haddad,et al.  Physiological modeling of toxicokinetic interactions: implications for mixture risk assessment. , 1998, Environmental health perspectives.

[23]  Melvin E. Andersen,et al.  Assessing interaction thresholds for trichloroethylene in combination with tetrachloroethylene and 1,1,1-trichloroethane using gas uptake studies and PBPK modeling , 2001, Archives of Toxicology.

[24]  D B Menzel,et al.  ES Series: Cancer Risk Assessment. 2. Physiological pharmacokinetic modeling. , 1987, Environmental science & technology.

[25]  Markus A Lill,et al.  The challenge of predicting drug toxicity in silico. , 2006, Basic & clinical pharmacology & toxicology.

[26]  H A el-Masri,et al.  Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment. , 1995, Toxicology.

[27]  R. Luecke,et al.  Drug elimination interactions: Analysis using a mathematical model , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[28]  J. Barrett,et al.  Application and Impact of Population Pharmacokinetics in the Assessment of Antiretroviral Pharmacotherapy , 2005, Clinical pharmacokinetics.

[29]  H J Clewell,et al.  Quantitative evaluation of the metabolic interactions between trichloroethylene and 1,1-dichloroethylene in vivo using gas uptake methods. , 1987, Toxicology and applied pharmacology.

[30]  T. Nikolskaya,et al.  A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT , 2006, Drug Metabolism and Disposition.

[31]  M. Danhof,et al.  Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. , 2005, Pharmacology & therapeutics.

[32]  Y. Sugiyama,et al.  Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. , 2003, Drug metabolism and pharmacokinetics.

[33]  Hiroaki Kitano,et al.  The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models , 2003, Bioinform..

[34]  Kristin K. Isaacs,et al.  Visualization-Based Analysis for a Mixed-Inhibition Binary PBPK Model: Determination of Inhibition Mechanism , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[35]  Sun Ku Lee,et al.  Comparison of pharmacokinetic interactions and physiologically based pharmacokinetic modeling of PCB 153 and PCB 126 in nonpregnant mice, lactating mice, and suckling pups. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[36]  R. Weaver.  Assessment of drug-drug interactions: concepts and approaches , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[37]  Thierry Langer,et al.  Predicting drug metabolism induction in silico. , 2006, Current topics in medicinal chemistry.

[38]  Hannu Raunio,et al.  Prediction of drug metabolism and interactions on the basis of in vitro investigations. , 2005, Basic & clinical pharmacology & toxicology.

[39]  Kairui Feng,et al.  The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.

[40]  David P Nickerson,et al.  A physiome standards-based model publication paradigm , 2009, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[41]  Ursula Gundert-Remy,et al.  Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda , 2007, Alternatives to laboratory animals : ATLA.

[42]  H. Einolf.  Comparison of different approaches to predict metabolic drug–drug interactions , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[43]  G. Smith,et al.  A physiologically based pharmacokinetic model linking plasma protein binding interactions with drug disposition. , 2009, Research in veterinary science.

[44]  R Tardif,et al.  Physiologically based modeling of the toxicokinetic interaction between toluene and m-xylene in the rat. , 1993, Toxicology and applied pharmacology.

[45]  R Tardif,et al.  A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[46]  R Tardif,et al.  Physiological modeling of the toxicokinetic interactions in a quaternary mixture of aromatic hydrocarbons. , 1999, Toxicology and applied pharmacology.

[47]  D. Leahy,et al.  Progress in simulation modelling for pharmacokinetics. , 2003, Current topics in medicinal chemistry.

[48]  Igor Goryanin,et al.  Kinetic modelling in systems biology , 2008 .

[49]  M. Andersen,et al.  Physiologically based pharmacokinetic analyses of simple mixtures. , 1994, Environmental health perspectives.

[50]  J E Simmons.  Application of physiologically based pharmacokinetic modelling to combination toxicology. , 1996, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[51]  M E Andersen,et al.  In vivo metabolic interactions of benzene and toluene. , 1990, Toxicology letters.